Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, discusses new promising therapies under investigation for light chain (AL) amyloidosis, such as bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cells. There are ongoing trials for anti-BCL2 agents, which can target the high proportion of AL amyloidosis clones that have the t(11;14) translocation. Additionally, anti-amyloid therapies with monoclonal antibodies are being investigated to promote the clearance of amyloid deposits and improve organ function. Brought together, these therapies tackle multiple aspects of AL amyloidosis pathogenesis, which will hopefully help to reduce disease burden. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
8 июл 2024
